Fundraising Fox

Jaguar Health

NASDAQ: JAGX

San Francisco, US · Delaware corporation · 1 known investors

Biotech

Founders & leadership

LC
Lisa ConteExecutive Officer, Director
CL
Carol LizakExecutive Officer
PC
Pravin ChaturvediExecutive Officer
SK
Steven KingExecutive Officer
JW
Jonathan WolinExecutive Officer
GD
Greg DivisDirector
JB
James BochnowskiDirector
JM
John Micek, IIIDirector
AJ
Anula JayasuriyaDirector
JS
Jonathan SiegelDirector

Investors · 1

DigitalDx VenturesreportedMenlo Parkvia Anula Jayasuriya · board

Reported raises · per SEC filings

Form D private placements
▶$2MraisedJul 2026 · 2 investors · Pharmaceuticals
Rule 506(b)
Jaguar Health (NASDAQ: JAGX) puts major dilution and incentive plan votes to investorsstocktitan.net · Jul 2026Jaguar Health registers 41M shares for resale | JAGX IPO Registration (S-1)stocktitan.net · Jul 2026
Officers, directors & promoters on the filing
  • Lisa ConteExecutive Officer, Director
  • Carol LizakExecutive Officer
  • Steven KingExecutive Officer
  • Jonathan WolinExecutive Officer
  • James BochnowskiDirector
  • John Micek IIIDirector
  • Anula JayasuriyaDirector
  • Jonathan SiegelDirector
  • Pravin ChaturvediExecutive Officer
Offering amount
$2M
Amount sold
$2M
First sale
Jun 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$40.8MraisedJul 2026 · 1 investors · Pharmaceuticals
Rule 506(b)
Jaguar Health secures $40M equity line, $2M prefs | JAGX 8-K Filingstocktitan.net · Jun 2026Jaguar Health (NASDAQ: JAGX) puts major dilution and incentive plan votes to investorsstocktitan.net · Jul 2026
Officers, directors & promoters on the filing
  • Lisa ConteExecutive Officer, Director
  • Carol LizakExecutive Officer
  • Steven KingExecutive Officer
  • Jonathan WolinExecutive Officer
  • James BochnowskiDirector
  • John Micek IIIDirector
  • Anula JayasuriyaDirector
  • Jonathan SiegelDirector
  • Pravin ChaturvediExecutive Officer
Offering amount
$40.8M
Amount sold
$40.8M
First sale
Jun 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.8MraisedNov 2025 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Carol LizakExecutive Officer
  • John Micek IIIDirector
  • Jonathan WolinExecutive Officer
  • Lisa ConteExecutive Officer, Director
  • Anula JayasuriyaDirector
  • Pravin ChaturvediExecutive Officer
  • Jonathan SiegelDirector
  • James BochnowskiDirector
  • Steven KingExecutive Officer
Offering amount
$10.8M
Amount sold
$10.8M
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedOct 2025 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan SiegelDirector
  • Steven KingExecutive Officer
  • James BochnowskiDirector
  • Carol LizakExecutive Officer
  • John Micek IIIDirector
  • Lisa ConteExecutive Officer, Director
  • Jonathan WolinExecutive Officer
  • Pravin ChaturvediExecutive Officer
  • Anula JayasuriyaDirector
Offering amount
$1M
Amount sold
$1M
First sale
Sep 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedSep 2025 · 15 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Lisa ConteExecutive Officer, Director
  • Steven KingExecutive Officer
  • Anula JayasuriyaDirector
  • Pravin ChaturvediExecutive Officer
  • Jonathan WolinExecutive Officer
  • Carol LizakExecutive Officer
  • James BochnowskiDirector
  • John Micek IIIDirector
  • Jonathan SiegelDirector
Offering amount
$2.4M
Amount sold
$2.4M
First sale
Sep 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedMay 2025 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Carol LizakExecutive Officer
  • Pravin ChaturvediExecutive Officer
  • James BochnowskiDirector
  • Lisa ConteExecutive Officer, Director
  • John Micek IIIDirector
  • Anula JayasuriyaDirector
  • Steven KingExecutive Officer
  • Jonathan SiegelDirector
  • Jonathan WolinExecutive Officer
Offering amount
$1.5M
Amount sold
$1.5M
Sales commissions
$190.9K
Placement agents
H.C. Wainwright & Co., LLC
First sale
May 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$60KraisedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Carol LizakExecutive Officer
  • Lisa ConteExecutive Officer, Director, Promoter
  • Jonathan B. SiegelDirector
  • Jonathan WolinExecutive Officer
  • James BochnowskiDirector
  • John Micek IIIDirector
  • Anula JayasuriyaDirector
  • Steven KingExecutive Officer
Offering amount
$60K
Amount sold
$60K
First sale
Sep 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedMay 2023 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Anula JayasuriyaDirector
  • Jonathan B. SiegelDirector
  • John Micek IIIDirector
  • Steven KingExecutive Officer
  • James BochnowskiDirector
  • Carol LizakExecutive Officer
  • Lisa ConteExecutive Officer, Director, Promoter
  • Jonathan WolinExecutive Officer
Offering amount
$1.8M
Amount sold
$1.8M
First sale
May 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news